Fitness & Wellness Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness & Wellness Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GTC Biotherapeutics, Inc.
GTC Biotherapeutics Reports First Quarter 2008 Financial Results
May 21st, 2008
GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) total net loss for the first quarter of 2008 was $8.2 million, or $0.10 per share, compared with $7.5 million, or $0.10 per share, in the first quarter of 2007. Revenue and expenses were both reduced from the prior period, primarily due to the timing of supplying product in the ATryn(R) program. Additional delivery of ATryn(R) to LEO Pharma A/S, GTC's commercial and development partner for Europe, Canada, and the Middle East, is planned for the second quarter of 2008. "GTC has continued to make strong operational progress during the first quarter, particularly in the progress of the ATryn(R) program and the related US BLA...
Source: Fitness & Wellness Business Week (2008-05-21)
|
